News
-
-
PRESS RELEASE
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. completes study on crofelemer for cancer therapy-induced diarrhea in dogs. Results expected to complement positive outcomes. Company plans to file effectiveness study by Q2 2026 -
-
-
-
PRESS RELEASE
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar Health's crofelemer program targeting intestinal failure shows promising results with reductions in parenteral support for pediatric patients. Company sponsors ELITE PED-GI Congress in Abu Dhabi -
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on Northwest Biotherapeutics Inc., providing insights into the company's late-stage oncology developments including the promising DCVax-L immunotherapy for glioblastoma -
-
PRESS RELEASE
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans single-blind extension phase for crofelemer trial in pediatric MVID patients, aiming to reduce parenteral support and improve clinical benefit. FDA supports protocol amendment
